Skip to main content

Table 1 Baseline characteristics

From: Third generation drug eluting stent (DES) with biodegradable polymer in diabetic patients: 5 years follow-up

%

IDDM

N = 213

Non-IDDMN

N = 675

P

(IDDM vs non-IDDM)

DM

N = 888

Non-DM

N = 2179

P

(DM vs non-DM)

Age (years) (mean ± SD)

66.10 ± 10.13

66.56 ± 10.13

0.740

66.45 ± 10.12

63.53 ± 11.16

<0.001

Male sex

67.14

76.93

0.065

72.30

80.27

<0.001

Previous PCI

36.15

33.13

0.455

33.86

31.40

0.199

Previous CABG

13.62

8.06

0.021

9.40

8.57

0.481

Previous MI

33.01

32.83

1.000

32.87

33.27

0.864

Current smoker

16.94

18.12

0.826

17.85

28.66

<0.001

Previous smoker

31.15

37.73

0.115

36.20

33.97

0.269

Hypercholesterolemia

78.57

76.30

0.573

76.85

68.65

<0.001

Hypertension

86.38

79.70

0.034

81.31

64.03

<0.001

Family history of CAD

29.27

29.65

1.000

29.56

38.93

<0.001

Peripheral vascular disease

15.08

10.46

0.098

11.57

4.61

<0.001

Congestive heart failure

12.12

4.60

<0.001

6.39

2.89

<0.001

Charlson comorbidity index (mean ± SD)

2.61 ± 1.67

2.10 ± 1.27

<0.001

2.21 ± 1.39

0.84 ± 0.91

<0.001

Baseline anginal status

      

 Stable angina

46.23

44.66

0.693

45.03

46.12

0.603

 Unstable angina

33.49

38.87

0.168

37.58

39.74

0.271

 Silent ischemia

20.28

16.47

0.213

17.38

14.13

0.026

 ACS

50.70

52.44

0.694

52.03

54.06

0.318

 STEMI in ACS

8.3

16.1

0.042

14.3

15.5

0.59

  1. PCI percutaneous coronary intervention, CABG coronary artery bypass graft, CAD coronary artery disease, DM diabetes mellitus, IDDM insulin-dependent diabetes mellitus, ACS acute coronary syndrome, SD standard deviation, vs versus, MI myocardial infarction, N number of patients